The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
NICE recommends venetoclax + obinutuzumab for frontline treatment of CLL
On November 10, 2020, the National Institute for Health and Care Excellence (NICE) recommended venetoclax in combination with obinutuzumab for patients with previously untreated chronic lymphocytic leukemia (CLL).
The guidance published by NICE indicates the routine National Healthcare Service (NHS) use of the venetoclax combination for the following indications:
- Adult patients with CLL with del(17p)/TP53 mutation
or
- Adult patients with CLL without del(17p)/TP53 mutation who are ineligible for treatment with fludarabine, cyclophosphamide, and rituximab (FCR) or bendamustine and rituximab (BR)
NICE has also recommended the use of venetoclax + obinutuzumab within the Cancer Drugs Fund for adult patients with CLL without del(17p)/TP53 mutation who are eligible for FCR or BR.
This approval provides a chemotherapy-free, 1-year fixed duration, first-line treatment option for patients with CLL, and will be available immediately to NHS patients in England.
The decision follows positive data from the phase III CLL14 trial (NCT02242942), which uncovered the superiority of venetoclax + obinutuzumab over chlorambucil + obinutuzumab in prolonging progression-free survival in patients with previously untreated CLL. For a comprehensive summary of the study design and efficacy outcomes from the CLL14 study, click here. The Lymphoma Hub also provided an overview of the full safety profile of the two regimens employed in the CLL14 trial, read it here.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content